Caplin Point Laboratories Limited has informed that the United States Food and Drug Administration (USFDA) conducted an unannounced inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi.

The inspection was conducted between August 5-9th, 2024 and concluded with zero observations. This outcome underscores the company’s strong commitment to maintaining the highest standards of integrity, quality, safety, and regulatory compliance in its operations.